Overview: Metachromatic Leukodystrophy Quantitative TestIntroduction: The Metachromatic Leukodystrophy Quantitative Test measures enzyme activity to diagnose metachromatic leukodystrophy, causing neurological decline. Following 2023 NORD guidelines, it uses quantitative assay for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected MLD.
Other Names: MLD Assay, Arylsulfatase A Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: MLD testing began in the 1970s with lysosomal storage disease research. Quantitative assays improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures enzyme activity to diagnose metachromatic leukodystrophy, guides treatment, and evaluates patients with neurological decline.
Test Parameters: 1. Arylsulfatase A Activity
Pretest Condition: No fasting required. Collect whole blood or fibroblasts. Report history of neurological decline or developmental delay.
Specimen: Whole Blood (EDTA, 2-5 mL), Fibroblasts (sterile container, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document neurological decline, developmental delay, or family history of lysosomal storage diseases. Include current medications.
Consent: Written consent required, detailing the tests purpose, MLD implications, and risks of sample collection.
Procedural Considerations: Uses quantitative assay to measure arylsulfatase A activity in specimens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for MLD diagnosis.
Factors Affecting Result Accuracy: Improper sample storage or low cell viability can affect results. Contamination may reduce specificity.
Clinical Significance: Reduced arylsulfatase A activity confirms MLD, guiding supportive care or enzyme replacement therapy. Normal activity may require genetic testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: ARSA gene sequencing, MRI, or nerve conduction studies to confirm MLD diagnosis.
Test Limitations: Pseudodeficiency of arylsulfatase A may mimic MLD; clinical correlation is needed. Sample quality affects sensitivity.
References: NORD MLD Guidelines, 2023; Neurology, Gieselmann V, 2022.
